RespireRx Pharmaceuticals Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$1.6M | −$2.6M | −$3.3M | −$1.7M | −$2.2M | −$4.2M |
| Net income | −$2.1M | −$3.1M | −$4.3M | −$2.1M | −$2.6M | −$4.3M |
| Total assets | $22,781 | $208,737 | $85,087 | $45,328 | $124,190 | $194,770 |
| Total liabilities | $11.9M | $10.2M | $8.1M | — | — | — |
| Equity | −$11.9M | −$10.0M | −$8.1M | −$7.4M | −$5.7M | −$4.4M |
| EPS (diluted) | $-0.04 | $-0.04 | — | — | — | — |
| Shares out. | 97.9M | 89.5M | 33.7M | 3.9M | 3.1M | 2.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- 17.7%
- Return on assets
- −9230.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 52250.1%
- Debt / equity
- —
- Book value / share
- $-0.12
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -29032.05distress
- Accruals / assets
- −8598.5%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2023
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2023
- NT 10-Qmissed a reporting deadline ↗May 15, 2023
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jones Timothy L.Officer — CEO and President | Sep 30, 2020 | Conversion | 4.4M | — |
| Margolis Jeff EliotOfficer — SVP, CFO, Secret'y & Treasurer | Sep 30, 2020 | Conversion | 91.9M | — |
| Margolis Jeff EliotOfficer — SVP, CFO, Secretary & Teasurer | Mar 22, 2020 | J | 4.5M | — |
| Lippa ArnoldOfficer — Exec. Chairman, CEO, CSO | Mar 22, 2020 | J | 4.5M | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureFeb 10, 2025
- Amended charter or bylawsSep 6, 2024
- Entered a material agreementAug 2, 2024
- Entered a material agreement · Other material eventJul 8, 2024
- Regulation FD disclosureMay 29, 2024
- Entered a material agreementApr 16, 2024
- Entered a material agreementFeb 2, 2024
- Entered a material agreement · Director / officer change · Regulation FD disclosureJan 22, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.